- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05985772
Operative vs Non-operative Management of Posterior-medial Meniscal Root Tears: A Randomized Multicenter Trial (RCT)
Study Overview
Status
Conditions
Detailed Description
This study is a pragmatic design, parallel group, randomized clinical trial in which 140 subjects with a diagnosed medial meniscus root tear based on MRI and confirmed intra-operatively will be randomized to one of two treatment arms. The first group (ARM 1) will be treated non-operatively with analgesics, physical therapy, and will be kept non-weight bearing for 6 weeks (to match the postoperative protocol). If no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2) (CONSORT Flow Diagram)) as determined by 3 month patient reported outcomes (PROs and operating study physician approval.
The second group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. A previously published protocol will be used to standardize the rehabilitation. (14) Subjects will be followed with patient reported outcomes, serial radiographs (3 views), and a magnetic resonance imaging (MRI) scan at 12 months to determine repair status, meniscal extrusion, and presence of degenerative changes. Subjects who crossover at 3 months will be evaluated using additional MRI imaging prior to assignment to the acute operative meniscal root repair pathway (ARM 2). These subjects will crossover from ARM 1 to ARM 2 without first performing the ARM 1, 3 month radiograph (x-rays-3 views). The 3-month radiograph (x-rays-3 views) will be performed 3 months post-operative.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Carla M. Edwards, PhD
- Phone Number: 312-563-5735
- Email: carla_edwards@rush.edu
Study Contact Backup
- Name: Jorge Chahla, MD
- Phone Number: (312) 432-2818
- Email: jorge.chahla@rushortho.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush University Medical Center
-
Contact:
- Carla M Edwards, PhD
- Phone Number: 312-563-5735
- Email: carla_edwards@rush.edu
-
Principal Investigator:
- Jorge Chahla, MD, PhD
-
Sub-Investigator:
- Adam Yanke, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- MRI-verified isolated tibial medial meniscus root tear
- Subject must be 18 years of age or older
Exclusion Criteria:
- Concurrent ligamentous knee pathology requiring surgical intervention (i.e. anterior cruciate ligament tear, posterior cruciate ligament tear, posterolateral corner injury, high-grade medial collateral ligament tear),
- Preoperative Kellgren-Lawrence grade of 3 or 4
- Inability to complete outcome questionnaires or comply with required postoperative imaging or MRI requirements, or medical contraindications to surgery or physical therapy.
- There will be no exclusion criteria regarding body mass index (BMI) or mechanical alignment, however subjects will be stratified in groups for further analysis (BMI less and over 35 and varus alignment below and over 3º of varus).
- Pregnancy
- Subjects < 18 years of age
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Non-operative Control (ARM 1)
Subjects randomized to the non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing.
This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks.
Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
|
The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing.
This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks.
Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
|
|
Experimental: Operative Intervention (ARM 2)
Subjects randomized to the operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment.
All surgically treated subjects, regardless if repairs were performed acutely or after cross over, will receive identical postoperative rehabilitation.
|
The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well.
For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analogue scale (VAS) for pain
Time Frame: Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
The Visual Analogue Scale (VAS) measures pain intensity.
The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
Ask the patient to rate their current level of pain by placing a mark on the line.
|
Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Western Ontario Meniscal Evaluation Tool (WOMET)
Time Frame: Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
We will measure symptoms of osteoarthritis (OA) of the knee using the Western Ontario Meniscal Evaluation Tool (WOMET).
The instrument has 16 items representing the domains of physical symptoms (nine items), sports/recreation/work/lifestyle (four items), and emotions (three items).This instrument has been validated for additional meniscal injury etiologies including degenerative tears.
|
Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
|
Knee Osteoarthritis and Outcomes Score (KOOS)
Time Frame: Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
The KOOS is a 42-item knee-specific questionnaire with five separately reported domains, including pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sports/recreation (5 items) and knee-related quality of life (4 items).
Domain scores represent the average of all items in the domain standardized to a score from 0 to 100.
This instrument has face validity and has demonstrated construct validity, excellent test-retest reliability for each domain (range, 0.75 to 0.93) and has been shown to be responsive to change in patients with knee osteoarthritis (OA).
|
Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
|
European Quality of Life Scale (Euro-QoL)
Time Frame: Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
The EuroQol (EQ) comprises two sections, the EQ-5D(5 level digit) index and the EQ-5D visual analogue scale (VAS).
The EQ-5D index is a 5 item standardized generic measure of HRQOL that includes domains of mobility, self-care, usual activities, pain and discomfort, and anxiety and depression.
Each item is scored using a 3-point response scale and each combination of response choices describes a health state.
|
Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
|
Lysholm knee score
Time Frame: Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
The Lysholm score is comprised of eight domains including limp, locking, pain, stair climbing, and use of supports, instability, swelling, and squatting, for a combined score ranging from 0-100.
|
Enrollment up to 12 months postoperatively (18 months if crossover at 3 months from ARM 1 to ARM 2)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jorge Chahla, MD, Rush University Medical Center Associate Professor and Surgeon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19082802
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meniscus Tear, Tibial
-
Zimmer BiometRecruitingMeniscus Lesion | Meniscus Tear, TibialFrance, Germany, Japan, United States
-
University of Kansas Medical CenterCompletedMeniscus Tear, TibialUnited States
-
Austin V StoneTerminatedAnterior Cruciate Ligament Tear | Tibial Meniscus Injuries | Tibial Meniscus Tears | Tibial Meniscus, TornUnited States
-
University of California, San FranciscoTerminatedMeniscus Lesion | Atrophy, Muscular | Meniscus Disorder | Meniscus Tear, Tibial | Meniscus, Torn TibialUnited States
-
Onze Lieve Vrouwe GasthuisCompletedOsteoarthritis, Knee | Meniscus Tear, Tibial
-
Eskisehir Osmangazi UniversityThe Scientific and Technological Research Council of TurkeyRecruitingArthralgia | Knee Injuries | Meniscus; Degeneration | Knee Pain Swelling | Meniscus Lesion | Meniscus Tear | Knee; Injury, Meniscus (Lateral) (Medial) | Meniscus; Laceration | Meniscus Injury, TibialTurkey
-
University Hospitals Cleveland Medical CenterCompletedPain, Postoperative | Postoperative Complications | Opioid Use | Meniscus Tear, Tibial | Ketorolac Adverse ReactionUnited States
-
Karadeniz Technical UniversityActive, not recruitingTibial Meniscus TearsTurkey (Türkiye)
-
Artromedical Konrad Malinowski ClinicRecruitingMeniscus; Degeneration | Meniscus Lesion | Meniscus Tear | Meniscus DisorderPoland
-
Austin V StoneWithdrawnMeniscus Lesion | Meniscus Tear | Meniscus Disorder | Meniscus; DerangementUnited States
Clinical Trials on Non-Operative Pain Management
-
The Cleveland ClinicTerminatedColorectal Cancer | Crohn Disease | Ulcerative Colitis | Diverticular DiseaseUnited States
-
Fondation Ophtalmologique Adolphe de RothschildTerminated
-
University of Missouri-ColumbiaTerminatedMetacarpal FractureUnited States
-
The Cleveland ClinicTerminatedCovid19 | Cholecystitis, Acute | Cholecystitis | Appendicitis | Cholecystitis; GallstoneUnited States
-
Hospital San Juan de Dios del Aljarafe de SevillaNot yet recruitingQuality of Life | Chronic Pain Syndrome | Patient Empowerment | Sensitization, CentralSpain
-
Massachusetts General HospitalCompleted
-
NorthShore University HealthSystemKimberly-Clark CorporationCompleted
-
VA Office of Research and DevelopmentRecruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedEmergencies | Hernia | Surgery--ComplicationsUnited Kingdom